- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
Celyad completes 30-day safety follow-up of first patient in NKG2D Phase I trial
11 June 2015 • Author: Victoria White
Celyad has completed the 30-day safety follow-up of the first patient enrolled in a Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy in cancer patients suffering from acute myeloid leukaemia (AML) or multiple myeloma (MM).
The NKG2D CAR T-cell is an autologous chimeric antigen receptor T lymphocyte (CAR T-cell) therapy constructed using the native sequence of natural killer cell (NK cell) receptors which, unlike traditional CAR technologies such as those targeting the CD19 antigen, has the potential to target a broad range of solid tumours and blood cancers by targeting ligands present on numerous types of cancer cells.
The first patient enrolled in Phase I dose escalation study suffers from AML. Following the infusion of the first dose of NKG2D CAR T-cell, no safety issues were reported. This marks an important step in demonstrating the safety of NKG2D CAR-T cell infusion at that dose and triggers the enrollment of the next two patients in the first dose cohort.
Full readout from the Phase I trial of NKG2D CAR-T cell infusion is expected in mid-2016
Dr. Christian Homsy, CEO of Celyad, commented, “At 30 days post NKG2D CAR-T cell infusion for this first patient, no safety issues were reported. This is a great milestone in validating our new CAR T-cell platform. We look forward to recruiting of the remaining patients in this first dose cohort.”
The full data readout from the Phase I trial is expected in mid-2016. The trial is designed to assess the safety and feasibility of NKG2D CAR T-cell as primary endpoints, with secondary endpoints including clinical efficacy.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific ReAgent Russell Finex Limited Sentronic GmbH Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited WITec GmbH Xylem Analytics YMC Europe GmbH Yusen Logistics